A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Starglo isn't applicable to a US population, an adcom rules.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
PF-08046037 joins PF-08046054 in clinical development.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
